Study of homoeopathic medicine in patients with Essential high blood pressure and anger management

Effectiveness of Homeopathic Medicines in Essential Hypertension with Anger Management - A Non controlled Experimental Study - nil

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/05/067291

Enrollment

Registered

2024-05-14

Start date

Unknown

Completion date

Unknown

Last updated

2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I10- Essential (primary) hypertension

Interventions

Intervention1: Homoeopathic Medicines in Essential Hypertension with Anger Management: Dose is selected as per the patients susceptibility, Frequency of followups is for 15-20 days, Route of administr

Eligibility

Inclusion criteria

Inclusion criteria: a. Patients Suffering from essential hypertension (pre-hypertensives: SBP 120-139 mm Hg, DBP 80-89 mm Hg, stage I hypertensives: SBP 140-159 mm Hg, DBP 90-99 mm Hg; stage II hypertensives: SBP more than or equal to 160 mm Hg, DBP more than or equal to 100 mm Hg; b. Patients on antihypertensive treatment c. Patients of age group 18 to 60 yrs. d. Patients with essential hypertension with no target organ affected e. All sexes f. Any socio- economic background

Exclusion criteria

Exclusion criteria: a. Provisional or confirmatory diagnosis of secondary HT. b. Gestational hypertension c. Malignant Hypertension d. Patients of severe complications of essential hypertension

Design outcomes

Primary

Measure	Time frame
1.To study Anger Assessment Ratings on STAXI-2 should reduce significantly at the end of the study when compared with the pre-test scores 2. To study Subjective Distress 3.To study Objective Parameters: -Systolic & Diastolic Blood Pressure Timepoint: 1. Duration of study: 18 months. 2. Duration of each case: Cases will be managed upto the date of improvement or observed for a periodof minimum 6 months. 3. Duration of follow up of each case:The follow ups will be taken at the interval of 15-20 days. 4. whole result of outcome will be explained at the end of 18 months	—

Measure

Time frame

1.To study Anger Assessment Ratings on STAXI-2 should reduce significantly at the end of the study when compared with the pre-test scores 2. To study Subjective Distress 3.To study Objective Parameters: -Systolic & Diastolic Blood Pressure Timepoint: 1. Duration of study: 18 months. 2. Duration of each case: Cases will be managed upto the date of improvement or observed for a periodof minimum 6 months. 3. Duration of follow up of each case:The follow ups will be taken at the interval of 15-20 days. 4. whole result of outcome will be explained at the end of 18 months

—

Secondary

Measure	Time frame
1.The outcome measures will be changes in the systolic and / or diastolic blood pressure at a timeline of six months. 2.The effect size was considered as the lowering of systolic and diastolic BP by a minimum of 15 mm and 6 mm of Hg, respectively. Thus, cases where this lowering in SBP and DBP was observed will be scribed as ‘improved’ and the rest ‘not improved’. 3.The study end-point will be lowering of BP following intervention. The primary safety end-point will be any adverse event during the study in any of the groups. The stopping guidelines will be, a marked deterioration of health condition and / or constant increase in BP among subjects in either groupTimepoint: 6 months	—

Measure

Time frame

1.The outcome measures will be changes in the systolic and / or diastolic blood pressure at a timeline of six months. 2.The effect size was considered as the lowering of systolic and diastolic BP by a minimum of 15 mm and 6 mm of Hg, respectively. Thus, cases where this lowering in SBP and DBP was observed will be scribed as ‘improved’ and the rest ‘not improved’. 3.The study end-point will be lowering of BP following intervention. The primary safety end-point will be any adverse event during the study in any of the groups. The stopping guidelines will be, a marked deterioration of health condition and / or constant increase in BP among subjects in either groupTimepoint: 6 months

—

Countries

India

Contacts

Public ContactDr Ashish A Bhagat

SJPESs HMC Kolhapur

phdsynopsis40@gmail.com9823195866

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026